Relay Therapeutics (RLAY) Non-Current Assets (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Non-Current Assets of $41.2 million for Q1 2026, down 31.07% year-over-year from $59.7 million in Q1 2025, and down 4.42% quarter-over-quarter from $43.1 million in Q4 2025.
Relay Therapeutics (RLAY) Non-Current Assets (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Non-Current Assets for 8 consecutive years, with $41.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 31.07% year-over-year to $41.2 million; the TTM figure through Mar 2026 stood at $178.6 million (down 29.96% YoY), while the FY2025 annual figure was $43.1 million, down 30.66% from the prior year.
- Non-Current Assets retreated to $41.2 million in Q1 2026 per RLAY's latest filing, from $43.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $81.4 million in Q3 2022 and bottomed at $33.6 million in Q2 2022.
- Historically, Non-Current Assets has averaged $61.2 million across 5 years, with a median of $65.0 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 149.27% — and 2026, when it plunged 31.07%.
- Relay Therapeutics' Non-Current Assets stood at $80.3 million in 2022, then declined by 7.96% to $73.9 million in 2023, then dropped by 15.95% to $62.1 million in 2024, then sank by 30.66% to $43.1 million in 2025, then decreased by 4.42% to $41.2 million in 2026.
- Business Quant data shows RLAY's Non-Current Assets at $41.2 million in Q1 2026, $43.1 million in Q4 2025, and $46.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | 39.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.38 Mn |
| Mar 31, 2026 | 41.15 Mn |
| Dec 31, 2025 | 43.05 Mn |
| Sep 30, 2025 | 45.99 Mn |
| Jun 30, 2025 | 48.45 Mn |
| Mar 31, 2025 | 59.70 Mn |
| Dec 31, 2024 | 62.09 Mn |
| Sep 30, 2024 | 64.99 Mn |
| Jun 30, 2024 | 68.28 Mn |
| Mar 31, 2024 | 71.34 Mn |
| Dec 31, 2023 | 73.88 Mn |
| Sep 30, 2023 | 75.16 Mn |
| Jun 30, 2023 | 77.67 Mn |
| Mar 31, 2023 | 79.17 Mn |
| Dec 31, 2022 | 80.27 Mn |
| Sep 30, 2022 | 81.42 Mn |
| Jun 30, 2022 | 33.63 Mn |
| Mar 31, 2022 | 34.09 Mn |
| Dec 31, 2021 | 32.20 Mn |
| Sep 30, 2021 | -638.60 Mn |